How to Buy First Tracks Biotherapeutics Stock
First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics, Inc. , situated in San Diego, California, specializes in pioneering new immunology-based treatments.
First Tracks Biotherapeutics stock last closed at $41.25, up 13.7% from the previous day, and has decreased N/A in one year. It has underperformed other stocks in the Biotechnology industry by N/A percentage points. First Tracks Biotherapeutics stock is currently +177.22% from its 52-week low of $14.88, and -17.35% from its 52-week high of $49.91.
At the moment, there are 35.73M TRAX shares outstanding. The market value of TRAX is $1.47B. In the last 24 hours, 1.03M TRAX shares were traded.
How to Buy First Tracks Biotherapeutics Stock
Wondering how to invest in First Tracks Biotherapeutics stock? Here's how.
- Decide where to buy First Tracks Biotherapeutics stock: You need to choose an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you choose where to buy First Tracks Biotherapeutics stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your investment account: Select your method of payment and add your information.
- Research First Tracks Biotherapeutics stock: The First Tracks Biotherapeutics ticker symbol is TRAX. Is First Tracks Biotherapeutics stock a good investment? Should you buy shares of TRAX? How do TRAX's underlying business fundamentals look? Do top analysts think First Tracks Biotherapeutics is a good buy? Why has TRAX's stock price moved recently? (Hint: Our stock market analysis website can help you evaluate if TRAX is a good stock to buy).
- Execute your TRAX trade: Decide if you will purchase TRAX shares at the current market price or use a limit order to purchase TRAX stock at a given price.
- Keep an eye on your investment in TRAX: Create a watchlist to important updates regarding your new investment in First Tracks Biotherapeutics stock.
Step 1: Decide where to buy First Tracks Biotherapeutics stock
You need an online brokerage account to access the NASDAQ market and buy TRAX stock.
Our recommended brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world financial markets: From Tech to Utilities, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the best brokerage, the next step is to fill out some personal details so you can invest in TRAX stock today.
How to Create a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal data to start your new brokerage account.
- Send your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you've created your account on our top ranked stock market app, you need to deposit funds:
Watch this video walkthrough for more details transferring money into your new brokerage account.
Step 4: Research First Tracks Biotherapeutics stock
Once you have decided on the best place to buy First Tracks Biotherapeutics stock, it's critical to research their stock before you invest, so you actually wrap your head around the risk and opportunity.
First Tracks Biotherapeutics Numbers
TRAX Due Diligence Checks
WallStreetZen was built to help average investors do more accurate fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on TRAX's stock page.
Is TRAX stock undervalued?
Investors use many financial metrics, analyses, models, and charts to gauge TRAX's intrinsic value.
Using relative valuations metrics:
- TRAX may be overvalued based on its P/B ratio of 8.73x, relative to Biotechnology industry P/B ratio of 5.13x
You can access more valuation analysis on TRAX's stock here.
Is TRAX a healthy company?
Passed Health Checks:
- There are more short-term assets than long-term liabilities on the TRAX balance sheet.
- TRAX has a low debt to equity ratio of 0.09.
- There are more short-term assets than short-term liabilities on the TRAX balance sheet.
Is it a good time to buy First Tracks Biotherapeutics stock, according to Wall Street analysts?
Out of 11 Wall Street analysts who monitor TRAX, the consensus analyst rating on TRAX is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they investment advice.
Latest TRAX Analyst Recommendations
Emily Bodnar, a bottom 2% analyst from HC Wainwright & Co. reiterates TRAX with a buy rating and maintains their TRAX price target from $57.00 to $57.00, on Sep 3, 2026.
Etzer Darout, a top 2% analyst from Barclays maintains TRAX with a strong buy rating and raises their TRAX price target from $48.00 to $65.00, on Aug 13, 2026.
Martin Fan, a top 8% analyst from Wedbush maintains TRAX with a buy rating and raises their TRAX price target from $60.00 to $70.00, on Aug 13, 2026.
Yasmeen Rahimi, a top 6% analyst from Piper Sandler maintains TRAX with a strong buy rating and raises their TRAX price target from $54.00 to $95.00, on Aug 13, 2026.
Piper Sandler's Yasmeen Rahimi raised their price target on First Tracks Biotherapeutics (NASDAQ: TRAX) by 75.9% from $54 to $95 on 2026/08/13. The analyst maintained their Strong Buy rating on the stock.
First Tracks Biotherapeutics reported its Q2 2026 earnings.
Raising their price target after a post-print meeting with management, Rahimi cited:
- Competitor clinical validation of anti-CD122 mechanism of action.
- Management detailing how ANB033's Phase 1b celiac disease Cohort 1 enrollment is complete with data remaining on-track for Q4 2026.
Earnings Report
For Q2 2026, First Tracks Biotherapeutics reported:
- EPS of $(0.95), up from Q2 2025's $(1.47).
- Revenue of $0.00.
Management did not provide financial guidance in its press release.
President & CEO Daniel Faga commented: “First Tracks continues to execute against a broad development strategy for our potentially best-in-class CD122 antagonist, ANB033, and anticipates treating patients across four indications in 2027.
"We believe ANB033 is uniquely positioned to deliver differentiated clinical and biological outcomes across multiple immune-mediated diseases.
“In celiac disease, FDA’s Fast Track designation for ANB033 underscores both the urgency of the significant unmet need for patients and the potential of this program.
"We will report top-line data from Cohort 1 of the Phase 1b trial in Q4 2026, evaluating ANB033's potential to prevent gluten-induced mucosal injury.
"Cohort 2 of this study is enrolling patients with disease across a wide range of histologic and symptom severity at baseline with the goal of generating deeper insights into timing to mucosal healing and disease biology.
"We anticipate reporting these data in Q1 2027, followed by top-line data from our Phase 1b trial of ANB033 in eosinophilic esophagitis in Q3 2027.”
Michael Yee, a top 11% analyst from UBS maintains TRAX with a strong buy rating and raises their TRAX price target from $45.00 to $65.00, on Aug 10, 2026.
You can dig deeper into what analysts are forecasting on the First Tracks Biotherapeutics stock forecast page.
TRAX Momentum
Latest Insiders Trades at TRAX
Over the past 12 months, insiders at TRAX have sold more shares than they have bought.
J. Anthony Ware, Director of TRAX, was the latest TRAX insider to buy. They bought $225,381.10 worth of TRAX stock on Sep 2, 2026.
Learn more about who owns TRAX shares here.
Can I get consistent income from TRAX stock?
No, First Tracks Biotherapeutics doesn't provide an income stream by paying out dividends.
TRAX Social Trading Data
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Execute your TRAX trade
You have two primary options:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are usually fine for most investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a given price, place a limit order.
Hit the Open Trade button and eToro will place the order.
If you require more assistance buying stocks on eToro, click the helpful video below:
Step 6: Keep an eye on your investment in TRAX
Now that you own some TRAX shares, you'll want to stay up-to-date on your new company.
Put TRAX on a watchlist to track the latest developments regarding your TRAX stock.
TRAX Feed
How to Buy Stock in First Tracks Biotherapeutics
To reiterate, here are the 6 steps for buying First Tracks Biotherapeutics stock:
- Decide where to buy First Tracks Biotherapeutics stock
- Open your brokerage account
- Fund your investment account
- Research First Tracks Biotherapeutics stock
- Execute your TRAX trade
- Keep an eye on your investment in TRAX
If you need a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to get the latest scoop on your investment in First Tracks Biotherapeutics, create a watchlist on WallStreetZen today.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.